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Abstract 
Background: There is a paucity of global data on cardiovascular disease (CVD) prevalence in people with type 2 
diabetes (T2D). The primary objective of the CAPTURE study was to estimate the prevalence of established CVD and 
its management in adults with T2D across 13 countries from five continents. Additional objectives were to further 
characterize the study sample regarding demographics, clinical parameters and medication usage, with particular 
reference to blood glucose-lowering agents (GLAs: glucagon-like peptide-1 receptor agonists and sodium-glucose 
co-transporter-2 inhibitors) with demonstrated cardiovascular benefit in randomized intervention trials.
Methods: Data were collected from adults with T2D managed in primary or specialist care in Australia, China, Japan, 
Czech Republic, France, Hungary, Italy, Argentina, Brazil, Mexico, Israel, Kingdom of Saudi Arabia, and Turkey in 2019, 
using standardized methodology. CVD prevalence, weighted by diabetes prevalence in each country, was estimated 
for the overall CAPTURE sample and participating countries. Country-specific odds ratios for CVD prevalence were 
further adjusted for relevant demographic and clinical parameters.
Results: The overall CAPTURE sample included 9823 adults with T2D (n = 4502 from primary care; n = 5321 from 
specialist care). The overall CAPTURE sample had median (interquartile range) diabetes duration 10.7 years (5.6–
17.9 years) and glycated hemoglobin 7.3% (6.6–8.4%) [56 mmol/mol (49–68 mmol/mol)]. Overall weighted CVD and 
atherosclerotic CVD prevalence estimates were 34.8% (95% confidence interval [CI] 32.7–36.8) and 31.8% (95% CI 
29.7–33.8%), respectively. Age, gender, and clinical parameters accounted for some of the between-country variation 
in CVD prevalence. GLAs with demonstrated cardiovascular benefit were used by 21.9% of participants, which was 
similar in participants with and without CVD: 21.5% and 22.2%, respectively.
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Introduction
Cardiovascular disease (CVD) remains the largest cause 
of diabetes-related morbidity and mortality [1, 2]. Sys-
tematic reviews indicate there is an approximately two-
fold higher risk of CVD in people with versus without 
diabetes after adjustment for conventional risk factors [3, 
4]. Given the large clinical burden associated with CVD 
complicating type 2 diabetes (T2D), international dia-
betes and cardiology position statements and guidelines 
have been updated to encompass the combined manage-
ment of T2D and CVD [5–7]. These updates have been 
informed by cardiovascular (CV) outcome trials dem-
onstrating superiority in CV outcomes for some blood 
glucose-lowering agents (GLAs) versus placebo in people 
with T2D and established CVD or at high CVD risk [6, 
8]. The glucagon-like peptide-1 receptor agonists (GLP-1 
RAs) and sodium-glucose co-transporter-2 inhibitors 
(SGLT2is) with demonstrated CV benefit are now rec-
ommended as first [5] or second-line [6, 7] GLAs in this 
context.
The impact of the updated guidelines on real-world 
clinical practice should be of interest to clinicians and 
policy makers, and its evaluation requires robust con-
temporary estimates of CVD prevalence and manage-
ment in people with T2D that can be monitored over 
time. However, the current understanding of the global 
prevalence of, and between-country variation in, diabe-
tes-related complications, including CVD, is limited [9]. 
Available CVD prevalence data in people with T2D are 
mostly from regional or national studies conducted in the 
US [10] and some European countries [11–15]. Direct 
comparisons between countries are complicated by dif-
ferences in study methodology, including the population 
sampled and definition of CVD. Estimates of the CVD 
burden in some countries have been based on studies that 
sampled selected patient populations (such as from spe-
cialist care) or that utilized model-based estimates rather 
than real-world data [16]. A review paper estimated CVD 
to affect 32.2% of individuals with T2D worldwide, based 
on a systematic review of scientific literature published 
between 2007 and 2017 [16] that would not reflect recent 
changes in epidemiology and management of T2D and is 
now considered outdated.
The primary objective of the present study was to esti-
mate the contemporary prevalence of established CVD in 
adults with T2D across a range of countries and several 
continents using standardized methodology. Secondary 
objectives were to estimate the prevalence of high CVD 
risk in adults with T2D without established CVD (full 
results to be published elsewhere) and to further charac-
terize the study sample regarding demographics, clinical 
parameters, CV medication and GLA usage, with par-




CAPTURE was a non-interventional, cross-sec-
tional study conducted at 214 centers across 13 coun-
tries (NCT03786406 [Europe] and NCT03811288 
[non-Europe]). The countries were from Australasia 
(Australia), East Asia (China and Japan), Europe (Czech 
Republic, France, Hungary, and Italy), Latin America 
(Argentina, Brazil, and Mexico), and the Middle East 
(Israel, Kingdom of Saudi Arabia and Turkey). The study 
protocols were approved by the appropriate independ-
ent ethics committees and relevant institutional review 
boards. The study was conducted in accordance with the 
Declaration of Helsinki [17], International Society for 
Pharmacoepidemiology Good Pharmacoepidemiology 
Practices [18], and local regulations. All participants pro-
vided written informed consent prior to participation.
Local medical affairs personnel from participating 
countries, who were employed by the sponsor, provided 
information on the management of people with T2D, 
including types of physicians managing T2D in routine 
clinical practice (primary care practitioners, diabetolo-
gists, endocrinologists, cardiologists, and other special-
ists) and types of practices (primary care and specialist 
settings, including different types of hospitals) to a con-
tract research organization for consideration of site selec-
tion. Final participating sites were chosen by the contract 
research organization and approved by the sponsor on 
the basis that they were as representative as possible 
for each country. Factors considered were geographi-
cal spread and the division of patients being treated at 
Conclusions: In 2019, approximately one in three adults with T2D in CAPTURE had diagnosed CVD. The low use of 
GLAs with demonstrated cardiovascular benefit even in participants with established CVD suggested that most were 
not managed according to contemporary diabetes and cardiology guidelines.
Study registration NCT03786406 (registered on December 20, 2018), NCT03811288 (registered on January 18, 2019).
Keywords: Non-interventional study, Type 2 diabetes, Cardiovascular disease, Atherosclerotic cardiovascular disease, 
Prevalence, Glucagon-like peptide-1 receptor agonists, Sodium-glucose co-transporter-2 inhibitors
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private and public centers, as well as the degree of spe-
cialization at each site. The ratio of participants from pri-
mary to specialist care sites in each country was chosen 
to approximate the assumed distribution of adults with 
T2D managed in these settings according to available 
local data. No primary care sites were included in China, 
Hungary, or Italy as people with T2D in these coun-
tries are primarily, although not exclusively, managed 
in specialist care. In Italy, local health system organiza-
tion rules mean that new prescriptions for GLAs can-
not be provided in primary care. In China, patients with 
T2D consult hospital doctors as their primary contact. 
In Hungary, patients with T2D are mainly managed in 
a specialist care setting with limited influence from pri-
mary care on decisions regarding GLAs with CV benefit.
At each participating site, consecutive, eligible 
adults aged ≥ 18  years (≥ 20  years in Japan) at the time 
of informed consent who had been diagnosed with 
T2D ≥ 180 days prior to providing informed consent and 
who were attending the site as part of their routine visit 
to their treating physician were invited to participate 
by the treating physician during a 90-day time window. 
Exclusion criteria were a diagnosis of type 1 diabetes, 
known congenital heart disease or malformation, pre-
vious participation in this study (provided informed 
consent for inclusion at a prior visit during the data col-
lection period), and mental incapacity or language bar-
riers that precluded an adequate understanding of, or 
cooperation with, study requirements.
The invitation to participate, provision of informed 
consent, and data collection took place during a single, 
routine health visit at each site. In all countries, the treat-
ing physician or a trained delegate collected data using a 
standardized electronic case report form, and data were 
transferred to a central database via a web-based data 
capture system. Relevant data were collected from par-
ticipants’ medical records. The physician verbally asked 
participants for any information that was missing from 
the medical record. The study protocols did not mandate 
screening for, or adjudication of, the presence of compli-
cations .
Definitions of variables studied
Established CVD was defined as a diagnosis of any of the 
following conditions in participants’ medical records: 
cerebrovascular disease, coronary heart disease (CHD), 
heart failure, cardiac arrhythmia or conduction abnor-
malities, aortic disease, peripheral artery disease (PAD), 
or carotid artery disease (see Additional file 1: Table S1 
for the full list and definitions). Similarly, CVD was cat-
egorized as atherosclerotic CVD (ASCVD) when there 
was a diagnosis of any of the following CV conditions: 
cerebrovascular disease, CHD, PAD, or carotid artery 
disease [7]. For analysis purposes, participants were 
stratified into two groups based on the presence (CVD 
group) or absence (non-CVD group) of established CVD.
Available demographic, anthropometric, and clinical 
parameters were collected, in addition to selected medi-
cal history, GLAs, and CV medications (listed in Addi-
tional file  1: Methods S1). Only current medications or 
those discontinued within the previous 3  months were 
recorded. During analysis, GLAs were further grouped 
according to demonstrated CV benefit status in line with 
the 2020 American Diabetes Association guidelines [19] 
(and by March 2020, all had a CV indication in their US 
Food and Drug Administration label [20–25]). GLAs 
with demonstrated CV benefit included three GLP-1 
RAs (dulaglutide, liraglutide, and semaglutide) and three 
SGLT2is (canagliflozin, dapagliflozin, and empagliflozin).
Statistical analysis
Pre‑specified analyses
The prevalence (95% confidence interval [CI]) of CVD, 
ASCVD, CVD subtypes, and diagnoses were estimated 
for all countries together (overall) and for each coun-
try individually. Overall prevalence estimates were cal-
culated as weighted estimates to account for the size 
of the diabetes population in each country [26], as this 
was not accounted for in the sampling. Both the overall 
and country-level prevalence estimates were calculated 
as weighted estimates to account for any differences 
between the actual and planned sampling distribution of 
participants by healthcare setting (primary care:specialist 
care).
The study sample was characterized by demographics, 
clinical parameters, CV medication, and GLA usage, with 
particular reference to GLAs with demonstrated CV ben-
efit, presented for the overall study sample and separately 
for the CVD group and non-CVD group; data were not 
weighted.
Post hoc analyses
The number of affected vascular areas among those with 
CVD was calculated and stratified by gender. Three vas-
cular areas were analyzed, defined as coronary, cerebro-
vascular and peripheral.
To explore whether differences in estimated CVD 
prevalence between countries could be partially or fully 
explained by differences in demographic and clinical 
characteristics between the country samples, logistic 
regression models were used to calculate prevalence 
odds ratios (PORs) for CVD in each country using 
the overall CAPTURE study sample as the reference. 
The models were as follows: (1) crude; (2) adjusted for 
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age and gender; and (3) additionally adjusted for sta-
tistically significant clinical parameters identified via 
backwards selection (age, gender, diabetes duration, 
body mass index [BMI], glycated hemoglobin  [HbA1c], 
low-density lipoprotein cholesterol, high-density lipo-
protein cholesterol, smoking status, hypertension, 
nephropathy, neuropathy, and retinopathy). Param-
eters with a high proportion of missing data (albumi-
nuria, estimated glomerular filtration rate [eGFR] and 
physical activity) were not considered (Additional file 1: 
Table  S2). Any missing data for the included param-
eters were imputed for each country separately using 
fully conditional specification. Sensitivity analyses 
were conducted (1) without imputation of missing data 
for participants with complete covariate information 
and (2) including eGFR as a clinical parameter (both 
with and without imputation of missing data). Further 
details on the logistic regression analyses are available 
in Additional file 1: Methods S2.
Due to the large T2D population compared to the 
other study countries, China would have a large influ-
ence on the overall weighted CVD prevalence esti-
mates. As such, a sensitivity analysis was conducted 
where the prevalence calculations were repeated for all 
countries excluding China. These estimates were also 
calculated as weighted estimates to account for the size 
of the diabetes population of the 12 remaining coun-
tries [26].
In order to place the CAPTURE data in the context 
of two recent CV outcome trials, exploratory analyses 
assessed the number of participants with high CVD 
risk in the non-CVD group who were using a GLA with 
demonstrated CV benefit. Participants with high CVD 
risk were identified in the non-CVD group as satisfying 
relevant criteria from the REWIND [27] or DECLARE-
TIMI 58 [28] trials based on available CAPTURE data. 
To align as closely as possible with REWIND criteria, 
participants in the non-CVD group were categorized 
as being at high CVD risk if they were ≥ 60  years of 
age; were a current (any self-reported current tobacco 
use) or previous smoker (any self-reported his-
torical tobacco use); and were on anti-hypertensive 
medication or had elevated systolic blood pressure 
(≥ 140 mmHg) or had elevated diastolic blood pressure 
(≥ 95 mmHg) [27]. To align as closely as possible with 
DECLARE-TIMI 58 criteria, participants in the non-
CVD group were categorized as being at high CVD 
risk if they were ≥ 55 years of age if male or ≥ 60 years 
of age if female; and were either on anti-hypertensive 
medication or had both elevated systolic blood pressure 
(> 140  mmHg) and elevated diastolic blood pressure 
(> 90 mmHg) [28].
All statistical analyses were carried out using SAS, 
Version 9.4 (SAS Institute, Cary, NC, USA).
Results
Study sample
The overall study sample included 9823 adults with T2D 
(n = 4502 from primary care; n = 5321 from specialist 
care) (Additional file  1: Fig. S1 for study flow) who par-
ticipated between December 01, 2018 and September 30, 
2019. The median (interquartile range [IQR]) number of 
participants per site was 40 (25–57). The number and geo-
graphical distribution of study participants are presented 
in Additional file 1: Fig. S2. The median (IQR) age of the 
overall study sample was 64.0 years (56.0–71.0 years) and 
45.5% of participants were female (Table 1; additional data 
in Additional file 1: Table S3). Most (80.4%) participants 
had a BMI ≥ 25  kg/m2, and 70.1% had diagnosed hyper-
tension. The median (IQR)  HbA1c was 7.30% (6.60–8.40%) 
[56 mmol/mol (49–68 mmol/mol)] and diabetes duration 
was 10.7 years (5.6–17.9 years).
CVD prevalence
Among the 9823 study participants, over one third 
(n = 3582; 36.5%) had established CVD, with a weighted 
CVD prevalence estimated at 34.8% (95% CI 32.7–36.8%) 
across the 13 countries. CVD prevalence was lowest in 
the Kingdom of Saudi Arabia (18.0%) and highest in Israel 
(56.5%) (Fig.  1). Most (85.8%; n = 3074) cases of CVD 
were atherosclerotic, with the weighted ASCVD preva-
lence estimated at 31.8% (95% CI 29.7–33.8%) across the 
13 countries. The weighted prevalence of CVD subtypes 
and diagnoses are presented in Fig. 2 and Additional file 1: 
Table  S4. The most prevalent weighted CVD subtypes 
were CHD (17.7%), carotid artery disease (8.4%), and cer-
ebrovascular disease (7.2%). The overall weighted preva-
lence of heart failure was 2.4% (95% CI 2.1–2.7%), with a 
wide range from 0.2% in China to 14.5% in Israel (Addi-
tional file 1: Fig. S3). Overall, the weighted prevalence of 
CVD was similar in participants from primary versus spe-
cialist care (35.6% vs 34.6%) (not statistically analyzed).
In post hoc analyses that excluded China from the 
overall prevalence estimates, the weighted CVD preva-
lence was 36.6% (95% CI 35.4–37.7%) and heart failure 
prevalence was 6.9% (95% CI 6.3–7.6%) across the 12 
remaining countries.
Characteristics of the study sample by CVD status
In comparison with the non-CVD group, the CVD 
group was older (median age 68.0  years vs 62.0  years), 
had a higher proportion of males (61.3% vs 50.7%), and a 
longer duration of diabetes (median duration 13.0 years 
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n Data n Data n Data
Female, n (%) 9823 4465 (45.5) 3582 1388 (38.7) 6241 3077 (49.3)
Age, years, median [IQR] 9823 64.0 [56.0–71.0] 3582 68.0 [61.0–75.0] 6241 62.0 [54.0–69.0]
Race, n (%) 9822 3581 6241
 White 6487 (66.0) 2558 (71.4) 3929 (63.0)
 Asian 2133 (21.7) 718 (20.1) 1415 (22.7)
 Black or African American 158 (1.6) 66 (1.8) 92 (1.5)
 Other 1044 (10.6) 239 (6.7) 805 (12.9)
Diabetes duration, years, median [IQR] 9811 10.7 [5.6–17.9] 3577 13.0 [7.2–20.0] 6234 9.8 [4.8–15.9]
HbA1c, %, median [IQR] 9104 7.30 [6.60–8.40] 3289 7.40 [6.60–8.50] 5815 7.30 [6.50–8.30]
HbA1c, mmol/mol, median [IQR] 9104 56 [49–68] 3289 57 [49–69] 5815 56 [48–67]
FPG, mmol/L, median [IQR] 8204 7.60 [6.30–9.38] 2924 7.60 [6.21–9.43] 5280 7.60 [6.33–9.32]
Body weight, kg, median [IQR] 9742 79.3 [68.7–92.0] 3550 79.8 [69.0–92.0] 6192 79.0 [68.3–92.0]
BMI, kg/m2, median [IQR] 9611 29.0 [25.8–33.1] 3514 28.9 [25.7–33.1] 6097 29.1 [25.8–33.1]
Systolic blood pressure, mmHg, median [IQR] 9618 130.0 [120.0–140.0] 3531 130.0 [120.0–142.0] 6087 130.0 [120.0–140.0]
Diastolic blood pressure, mmHg, median [IQR] 9616 78.0 [70.0–82.0] 3529 76.0 [70.0–81.0] 6087 80.0 [70.0–83.0]
Total cholesterol, mmol/L, median [IQR] 8272 4.34 [3.68–5.14] 3001 4.05 [3.39–4.82] 5271 4.51 [3.83–5.26]
LDL cholesterol, mmol/L, median [IQR] 8090 2.39 [1.81–3.08] 2924 2.12 [1.62–2.77] 5166 2.54 [1.98–3.19]
HDL cholesterol, mmol/L, median [IQR] 7965 1.15 [0.98–1.40] 2907 1.11 [0.93–1.32] 5058 1.18 [0.99–1.42]
Triglyceride, mmol/L, median [IQR] 8466 1.60 [1.13–2.27] 3082 1.61 [1.14–2.30] 5384 1.59 [1.13–2.25]
eGFR, mL/min/1.73  m2, n (%) 7923 2888 5035
 > 89 2746 (34.7) 707 (24.5) 2039 (40.5)
 > 59–89 3512 (44.3) 1293 (44.8) 2219 (44.1)
 > 29–59 1450 (18.3) 757 (26.2) 693 (13.8)
 ≤ 29 215 (2.7) 131 (4.5) 84 (1.7)
Albuminuriaa, n (%) 6482 2433 4049
 Normal–mildly increased 4338 (66.9) 1396 (57.4) 2942 (72.7)
 Microalbuminuria 1607 (24.8) 774 (31.8) 833 (20.6)
 Macroalbuminuria 537 (8.3) 263 (10.8) 274 (6.8)
Medical history of hypertension, yes, n (%) 9643 6756 (70.1) 3522 2918 (82.9) 6121 3838 (62.7)
Familial hypercholesterolemia, yes, n (%) 6634 676 (10.2) 2342 246 (10.5) 4292 430 (10.0)
Retinopathy, n (%) 9818 3578 6240
 Yes 1455 (14.8) 725 (20.3) 730 (11.7)
 Yes (referred by participant) 399 (4.1) 144 (4.0) 255 (4.1)
 No 7964 (81.1) 2709 (75.7) 5255 (84.2)
Nephropathy, n (%) 9818 3579 6239
 Yes 1771 (18.0) 917 (25.6) 854 (13.7)
 Yes (referred by participant) 337 (3.4) 128 (3.6) 209 (3.3)
 No 7710 (78.5) 2534 (70.8) 5176 (83.0)
Neuropathy, n (%) 9817 3577 6240
 Yes 1774 (18.1) 867 (24.2) 907 (14.5)
 Yes (referred by participant) 459 (4.7) 168 (4.7) 291 (4.7)
 No 7584 (77.3) 2542 (71.1) 5042 (80.8)
Smoking status, n (%) 9725 3547 6178
 Current 1322 (13.6) 465 (13.1) 857 (13.9)
 Previous 2613 (26.9) 1268 (35.7) 1345 (21.8)
 Never 5790 (59.5) 1814 (51.1) 3976 (64.4)









n Data n Data n Data
Duration of  smokingb, years, median [IQR] 3733 28.0 [15.0–39.0] 1646 30.0 [20.0–40.0] 2087 25.0 [15.0–35.0]
Physical  activityc, days per week, n (%) 7492 2763 4729
 0–1 3599 (48.0) 1515 (54.8) 2084 (44.1)
 2–3 1613 (21.5) 497 (18.0) 1116 (23.6)
 4–5 883 (11.8) 264 (9.6) 619 (13.1)
 6–7 1397 (18.6) 487 (17.6) 910 (19.2)
To convert the values for glucose to mg/dL, divide by 0.0555. To convert the values for cholesterol to mg/dL, divide by 0.0259. To convert the values for triglycerides to 
mg/dL, divide by 0.0113. Data that were missing from the medical record but verbally confirmed by a participant were coded as ‘referred by participant’. Data were not 
weighted
a Defined as: normal–mildly increased, urinary excretion < 30 mg/24 h or UACR < 30 mg/g; microalbuminuria, urinary excretion 30–299 mg/24 h or UACR 30–299 mg/g; 
macroalbuminuria, urinary excretion ≥ 300 mg/24 h or UACR ≥ 300 mg/g
b Only applies to participants categorized as current or previous smokers
c Days with ≥ 30 min of moderate activity
BMI body mass index, CVD cardiovascular disease, eGFR estimated glomerular filtration rate, FPG fasting plasma glucose, HbA1c glycated hemoglobin, HDL high-
density lipoprotein, IQR interquartile range, LDL low-density lipoprotein, UACR urinary albumin to creatinine ratio
Fig. 1 Weighted CVD prevalence in people with type 2 diabetes across the 13 countries. Data presented overall and by country. Overall prevalence 
estimate (across the 13 countries) calculated as a weighted estimate to account for the size of the diabetes population of each country [26] and 
represented by the grey dotted line. Both the overall and country-level prevalence estimates were weighted by the sampling of participants by 
healthcare setting, if it was different from as planned. n numbers are the crude number of participants with CVD (i.e. they were not weighted). CI 
confidence interval, CVD cardiovascular disease, KSA Kingdom of Saudi Arabia, n number of participants with CVD
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vs 9.8 years) (Table 1; not statistically analyzed). In com-
parison with the non-CVD group, a higher proportion 
of participants in the CVD group had diagnosed hyper-
tension (82.9% vs 62.7%), renal dysfunction (microal-
buminuria, 31.8% vs 20.6%; macroalbuminuria, 10.8% 
vs 6.8%; eGFR ≤ 59  mL/min/1.73  m2, 30.7% vs 15.4%), 
were current or previous smokers (48.9% vs 35.6%), and 
reported low physical activity (0–1 day of physical activ-
ity per week, 54.8% vs 44.1%) (Table 1; additional data in 
Additional file  1: Table  S3). In contrast, median serum 
low-density lipoprotein cholesterol concentrations were 
lower in the CVD group versus the non-CVD group 
(2.12  mmol/L vs 2.54  mmol/L). The proportion of par-
ticipants with microvascular complications was higher 
in the CVD group compared with the non-CVD group 
(retinopathy: 24.3% vs 15.8%; nephropathy: 29.2% vs 
17.0%; neuropathy: 29.0% vs 19.2%).
Fig. 2 Overall weighted CVD prevalence in people with type 2 diabetes by CVD subtype and diagnosis. Data are overall prevalence estimates 
(95% CI), which were calculated as weighted estimates to account for the size of the diabetes population of each country [26] and the sampling 
of participants by healthcare setting, if it was different from as planned. Along the y-axis, CVD subtypes are in bold font, while the diagnoses 
contributing to each subtype are in plain font. Diagnoses are not mutually exclusive; one participant may have multiple diagnoses. *Categorized as 
ASCVD. †Included conduction abnormalities. ASCVD atherosclerotic CVD, AV atrioventricular, CHD coronary heart disease, CI confidence interval, CVD 
cardiovascular disease, PAD peripheral artery disease, SND sinus node dysfunction
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Fig. 3 Use of a GLAs, b GLAs with demonstrated CV benefit and c selected CV medications. Data are % and were not weighted. Data are 
presented for the CAPTURE study sample overall and stratified by CVD status. In b, GLAs with demonstrated CV benefit were defined per 2020 
American Diabetes Association guidelines [19] as GLP-1 RAs: dulaglutide, liraglutide, and semaglutide; and SGLT2is: canagliflozin, dapagliflozin, 
and empagliflozin. ACE angiotensin-converting enzyme, AGI alpha glucosidase inhibitor, ARB angiotensin II receptor blocker, CV cardiovascular, 
CVD cardiovascular disease, DPP-4i dipeptidyl peptidase-4 inhibitor, GLA blood glucose-lowering agent, GLP-1 RA glucagon-like peptide-1 receptor 
agonist, SGLT2i sodium-glucose co-transporter-2 inhibitor, SU sulfonylurea, TZD thiazolidinedione
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GLAs by CVD status
In total, 96.6% of the overall study sample were receiv-
ing at least one GLA from any class. Biguanides were 
less frequently prescribed in the CVD group than the 
non-CVD group (70.6% vs 78.5%), whereas insulin use 
was more common in the CVD group than in the non-
CVD group (44.8% vs 33.7%) (Fig. 3a). In total, 21.9% of 
participants were prescribed a GLA with demonstrated 
CV benefit, and this was similar in the CVD and non-
CVD groups (21.5% vs 22.2%) (Fig.  3b). SGLT2is were 
more frequently used than GLP-1 RAs (15.0% vs 8.6%) 
in the overall study sample, with a similar use of both 
therapeutic classes across the CVD and non-CVD 
groups.
In exploratory analyses, 2051 and 2498 participants 
from the non-CVD group were classified as having high 
CVD risk using some of the REWIND and DECLARE-
TIMI 58 criteria, respectively. In total, 22.2% (n = 456) of 
participants with high CVD risk according to REWIND 
criteria and 21.6% (n = 540) of participants with high 
CVD risk according to DECLARE-TIMI 58 criteria were 
using a GLA with demonstrated CV benefit.
CV medications by CVD status
Overall, 7461 participants (76.0%) were receiving any CV 
medication and it was more common in the CVD group 
than in the non-CVD group (89.8% vs 68.0%), with the 
same pattern across CV medication classes (Fig. 3c; not 
statistically analyzed). In the CVD group, statins were 
the most frequently utilized CV medications (64.2%), 
followed by beta-blockers (40.4%), acetylsalicylic acid 
(39.0%), angiotensin II receptor blockers (ARBs; 35.9%), 
calcium channel blockers (28.0%), and angiotensin-
converting enzyme (ACE) inhibitors (26.4%). In the 
non-CVD group, statin use also predominated (43.4%), 
followed by ARBs (26.4%), ACE inhibitors (20.0%), 
acetylsalicylic acid (19.1%), calcium channel block-
ers (18.9%), and beta-blockers (12.8%). Among partici-
pants at high CVD risk in the non-CVD group, statins 
were most frequently used (43.4%), followed by ARBs 
(30.3%), calcium channel blockers (24.3%), ACE inhibi-
tors (23.6%), acetylsalicylic acid (23.3%), and beta-block-
ers (14.0%).
Vascular areas affected according to gender
When analyzing the number of affected vascular areas 
in participants with CVD, data were available for 1134 
women and 1940 men. The proportion of participants 
with one vascular area affected was similar among men 
and women, although men were more likely to have more 
vascular areas involved than women (Additional file  1: 
Fig. S4).
PORs for CVD adjusted for age, gender, and clinical 
parameters
Differences in age and gender explained some of the vari-
ation in CVD prevalence between countries, as PORs in 
model 1 (age- and gender-adjusted) were closer to 1.00 
for some countries (Argentina, Australia, China, Israel, 
Kingdom of Saudi Arabia, and Turkey) than in the unad-
justed model (Additional file 1: Fig. S5). Adjustment for 
additional clinical parameters (model 2) appeared to 
explain further variation in CVD prevalence between 
countries observed in the unadjusted model, with PORs 
closer to 1.00 for all countries except China, France, and 
Mexico. However, there were still significant differences 
in CVD prevalence for some countries in comparison 
with the overall study sample after further adjustment, 
specifically lower odds of CVD for Kingdom of Saudi 
Arabia, Czech Republic, and France, in addition to higher 
odds of CVD for Israel, Brazil, and China (p < 0.05 for all 
comparisons; Additional file  1: Fig. S5). Findings from 
these adjusted analyses were consistent with sensitivity 
analyses without imputation of missing data (Additional 
file 1: Fig. S6) and including eGFR (both with and without 
imputation of missing data) (Additional file 1: Fig. S7).
Discussion
The overall weighted prevalence of CVD ascertained 
using standardized methodology in the present multi-
national study of adults with T2D from primary or spe-
cialist care settings was estimated at 34.8%. ASCVD 
accounted for most (85.8%) of this disease burden, with 
stable coronary artery disease, carotid artery disease, and 
stroke the major components.
The 2019 CAPTURE findings are in accordance with 
those reported by Einarson and colleagues [16] in their 
systematic literature review of 57 studies from 25 coun-
tries involving over 4.5 million adults with T2D con-
ducted between 1987 and 2015, which estimated a CVD 
prevalence of 32.2% [16]. Our weighted prevalence esti-
mate for ASCVD was also similar to that in the system-
atic review (31.8% vs 29.1%, respectively) [16]. Other 
available comparative data are from individual countries 
not included in CAPTURE. Nevertheless, our CVD prev-
alence estimate aligns with CVD data linked to hospital 
admissions for nearly 250,000 Scottish patients with T2D 
(32.5%) [14]. However, it is higher than that reported in a 
primary care survey of over 17,000 Danish patients with 
T2D (21.4%) [11], and our weighted ASCVD prevalence 
estimate is lower than the 45.2% reported in a cross-sec-
tional study of over 1.2 million adults with T2D from a 
US claims database in 2015 [10]. In addition to potential 
geographical differences, direct comparisons between 
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studies are complicated by heterogeneity in factors such 
as participant selection, study design, timing, and meth-
ods of CVD ascertainment. Nevertheless, the CAPTURE 
data, collected using standardized methodology across 
13 countries, make progress in addressing the need for 
more uniform epidemiological data relating to the global 
CVD burden [29].
In the present study, post hoc analyses were carried out 
to identify explanations for the between-country vari-
ation in CVD estimates. Differences in age and gender 
accounted for some of the observed variation between 
countries, while adjustment for additional clinical param-
eters further attenuated individual country differences 
from the pooled estimate. However, even after additional 
adjustment for potentially confounding parameters, there 
were significantly lower odds of CVD in the Kingdom 
of Saudi Arabia, Czech Republic, and France, contrast-
ing with significantly higher odds in Israel, Brazil, and 
China, as compared with the overall CAPTURE study 
sample. These between-country differences might reflect 
variation in the sites selected, genetic and/or lifestyle 
factors, healthcare accessibility and delivery, CV medi-
cation use, medical record characteristics, CVD screen-
ing practices, and even competing risk of death from 
non-diabetes-related causes [30, 31], factors that were 
not directly addressed in CAPTURE. Our country-level 
CVD prevalence estimates are similar to those reported 
by Einarson and colleagues [16] in their systematic litera-
ture review, wherein the prevalence in China was 33.9% 
in CAPTURE vs 28.4% in the systematic literature review. 
However, there was variation among the CVD estimates 
for the other countries in CAPTURE with outlying odds 
when compared with available data (Saudi Arabia: 18.0% 
vs 30.0%; France: 34.2% vs 53.9%; Brazil: 43.9% vs 27.5%, 
all for CAPTURE vs the systematic literature review 
[16], respectively). A detailed exploration of outliers was 
beyond the scope of the present study. With a large diabe-
tes population, China accounted for most of the weight-
ing and may have substantially influenced the results. 
However, post hoc analyses excluding China found that 
the overall weighted CVD prevalence was only margin-
ally higher (1.8 percentage points) for the remaining 12 
countries, despite a more pronounced influence of China 
on the weighted heart failure prevalence, which was 4.2 
percentage points higher for the remaining 12 coun-
tries. This large variation in heart failure prevalence may 
be attributed to underreporting and missed diagnoses, 
which may vary considerably between countries, depend-
ing on their screening and diagnostic capabilities [32].
Motivated by evidence that ASCVD is largely prevent-
able, many countries are starting to implement policies 
and practices that aim to decrease this burden in people 
at high risk, including those with T2D [29, 33]. Effective 
action to reduce the global burden of CVD in people 
with T2D requires reliable data on prevalence, risk fac-
tors, medication use, and the barriers to prevention and 
treatment [34]. Our findings indicate that fewer than 
one in four adults with T2D and established CVD use a 
GLA with demonstrated CV benefit. In 2015, when rela-
tively few relevant CV outcome trial data were available, 
an understandably lower use of GLP-1 RAs (7.9%) and 
SGLT2is (8.8%) was reported in over 500,000 US adults 
with T2D and established ASCVD [10].
Additionally, our findings indicate that a relatively low 
proportion of adults with T2D without established CVD 
but at high CVD risk in CAPTURE – approximately 20% 
– used a GLA with demonstrated CV benefit. This has 
potential clinical implications as REWIND found a non-
significant trend to fewer major adverse CV events with 
dulaglutide versus placebo in patients with CV risk fac-
tors but without CVD (hazard ratio [HR] 0.87, 95% CI 
0.74–1.02) [27], and DECLARE-TIMI 58 reported a non-
significant trend towards a lower rate of a composite of 
CV death or hospitalization for heart failure with dapa-
gliflozin versus placebo in the same subgroup (HR 0.84, 
95% CI 0.67–1.04) [28].
The proportions of patients using GLAs with demon-
strated CV benefit may change with the implementation 
and influence of recent updates to diabetes/cardiology 
guidelines that now recommend a GLP-1 RA or SGLT2i 
with demonstrated CV benefit as first- or second-line 
GLA in people with T2D and established CVD or at 
high/very high CVD risk [5–7]. The future impact of 
these updates on real-world clinical practice will be of 
interest, and our contemporary data provide a bench-
mark against which relevant trends can be monitored. 
Indeed, regional differences in diabetes and cardiology 
treatment guidelines, as well as approvals and reimburse-
ment of individual medications including GLAs, are also 
likely to influence the use of GLAs with CV benefit at a 
country level. For example, in Brazil, physicians have the 
ability to prescribe any class of GLA and are limited only 
by financial considerations. In France, SGLT2is where not 
approved for use at the time of the CAPTURE study, and 
even today, GPs have the ability to prescribe GLP-1 RAs 
but are only permitted to renew prescriptions of SGLT2is 
after they have been initiated by a specialist. In the King-
dom of Saudi Arabia, the availability of GLP-1 RAs and 
SGLT2i GLAs is dependent on the purchasing decisions, 
policies and prescribing privileges in individual govern-
mental hospitals.
A treatment gap exists for other evidence-based thera-
pies. For example, a smaller than recommended propor-
tion of participants with established CVD in CAPTURE 
were using statins (64.2%) or acetylsalicylic acid (39.0%) 
[6, 35]. In patients with known CVD, acetylsalicylic acid 
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reduces CV events, with the benefits outweighing the 
risk of major bleeding [36]. Statins have also been found 
to be effective in reducing CV events in patients with 
or without established CVD [37]. The CAPTURE data 
highlight the potential for improved use of non-glycemic 
CV pharmacotherapy for people with T2D and CV risk 
factors. Notably, glycemia, as assessed by  HbA1c, was 
relatively well controlled in the overall CAPTURE study 
sample (median 7.3% [56  mmol/mol]). This is in align-
ment with the  HbA1c levels reported by similar studies 
that estimated CVD prevalence in patients with T2D 
in primary care (mean 6.9% [52  mmol/mol]) [11] and 
admitted to hospital (median 7.2% [55 mmol/mol]) [14], 
albeit in other European settings.
The CAPTURE study has several strengths. It was 
cross-sectional and multinational in design, with con-
sistent methodology for data collection across different 
healthcare systems through use of a standardized elec-
tronic case report form. Participants were recruited from 
both primary and specialist care. Broad inclusion criteria 
were used to ensure that the study sample was as repre-
sentative as possible of the general adult T2D population, 
with implications for the generalizability of the findings. 
As evidenced by key demographic and clinical charac-
teristics, the participants spanned a wide spectrum of 
disease. Our findings provide contemporary prevalence 
estimates for several non-US countries where up-to-
date data were limited or absent [16]. Furthermore, our 
findings may provide valuable background data for local 
healthcare payers and policy makers to assist with evalu-
ating strategies to reduce CVD risk in adults with T2D. 
The application of our findings to the design of CV out-
come trials in the study countries could enhance the 
generalizability of their results by informing trial entry 
criteria and aiming to increase the representative nature 
of the trial sample compared with the general T2D 
population.
The present study has limitations. It is possible that 
our prevalence data are overestimates, as there may be a 
tendency for people with complications to consult their 
healthcare provider more frequently than the general 
T2D population. This form of ascertainment bias could 
explain why the CVD prevalence was similar in primary 
and specialist care. Additionally, very ill people with rela-
tively high rates of complications including CVD may 
have been unable to attend routine healthcare visits. We 
cannot exclude the possibility of consent bias, a potential 
limitation of any study requiring participants’ consent for 
inclusion, in that individuals willing to participate in the 
study may not have been fully representative of the gen-
eral population of patients with T2D. Medication use may 
have been influenced by country-specific guidelines for 
management of patients with T2D and between-country 
differences in approvals and reimbursement of individual 
medications and GLA classes. Furthermore, our study 
was non-interventional and did not mandate screening 
for, or adjudication of, the presence of complications. Our 
findings relied on the clinical capabilities and documen-
tation specific to each participant’s healthcare setting. 
The non-interventional nature of CAPTURE meant that 
some participants may have had undiagnosed or misdi-
agnosed CVD, particularly in clinics or countries where 
relevant investigations were not recommended, there was 
a lack of diagnostic capability, or where medical records 
were fragmented or incomplete. As it was important to 
identify a study population representative of patients 
with T2D regularly attending primary and/or second-
ary diabetes centers across the different countries and 
guarantee accuracy in data collection, the choice of par-
ticipating sites in primary and specialist care was based 
on recommendations from personnel with knowledge of 
the local health system who were employed by the spon-
sor rather than real-world country-specific data, with the 
possibility of selection bias. However, final participating 
sites were selected by the contract research organization 
(and approved by personnel employed by the sponsor) to 
optimize the accuracy of CVD data collection.
Conclusions
CAPTURE found that approximately one in three adults 
with T2D had established CVD. ASCVD accounted for 
most of this burden, with stable coronary artery dis-
ease, carotid artery disease, and stroke being the major 
contributors. Most participants with CVD were not 
managed according to the most recent diabetes and car-
diology guidelines, implying potential scope for reducing 
the excess risk through evidence-based interventions. 
Our data provide a benchmark against which trends can 
be monitored in order to evaluate the implementation of 
recent international guidelines.
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